Skip to main content
letter
. 2019 Aug;104(8):e345–e348. doi: 10.3324/haematol.2018.205302

Figure 2.

Figure 2.

During decitabine therapy, changes in percentage of immunohistochemistry (IHC) TP53-positive cells parallel closely the changes in TP53 mutation variant allele frequency (VAF) levels. Correlation between TP53 VAF, TP53 IHC and blast percentages and representative micrographs of TP53 staining in serial bone marrows from TP53-mutated patient (patient 1004) at different time points during decitabine therapy (A). Correlation between TP53 VAF, TP53 IHC and blast percentages in two more TP53-mutated patients treated with decitabine (B and C). Significant positive association between TP53 positivity and TP53 VAF during decitabine therapy (D). Significant positive association between TP53 positivity and blast % during decitabine therapy (E).